Get Connected:

 

Latest News

PBM, Retail Chain Partner to Purchase Specialty Drugs
Specialty drugs are a large driver of health care spending. 
A look at the top stories in the world of pharmacy from last week.
Top news of the day from across the health care landscape.
Medicaid was a leading payer for inpatient hospital stays among multiple age groups over a 15-year period.
A report from the Center for Medicare & Medicaid Services outlines projected health care spending between 2017 and 2026.
Top news of the day from across the health care landscape.
CAR T-cell therapies tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) have been scrutinized for their high costs.
Bone fractures associated with type 2 diabetes may be linked to a change in collagen.
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events